Genetic Studies of Early-onset Dementia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04906863

Enrollment

1000

Registered

2021-05-28

Start date

2016-09-14

Completion date

2028-04-30

Last updated

2025-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Early Onset

Keywords

Alzheimer's Disease, Memory loss, Early-onset Alzheimer's disease, Mild cognitive impairment, Normal cognition, Dementia, Genetics

Brief summary

The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease, mild cognitive impairment and other dementias.

Detailed description

The study population includes individuals affected by Alzheimer's Disease, mild cognitive impairment, other dementias, cognitively healthy individuals without memory problems, or their family members. Ascertainment is across both males and females, and all race and ethnic groups.

Interventions

GENETICBlood draw

Blood draw for identification of genetic variants associated with the development of memory problems

OTHERNeurocognitive testing

Brief memory test

OTHERMedical questionnaire

Collection of medical history

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 18 years and older * Individuals diagnosed with dementia, their family members and unrelated healthy controls without dementia.

Exclusion criteria

-Individuals with competing diagnosis such as Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc., unless family members of a dementia affected individual

Design outcomes

Primary

Measure	Time frame	Description
Genetic risk variants associated with early-onset dementia	2 years	Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers.
Changes in blood biomarkers in early-onset dementia	2 years	Blood biomarkers including plasma amyloid beta and tau protein will be assessed in blood and correlated with onset and progression of memory loss and functional impairment

Countries

United States

Contacts

Primary ContactPamela Del Rosario

pd2727@cumc.columbia.edu212-304-7284

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026